NCT03025269View on ClinicalTrials.gov

Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

January 8, 2022

Study Completion Date

January 8, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab

This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments

Trial Locations (1)

14203

Jacobs Institute, Buffalo

All Listed Sponsors
lead

University at Buffalo

OTHER

NCT03025269 - Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis | Biotech Hunter | Biotech Hunter